

Claims

1. The use of antagonists of placental growth factor for the manufacture of a medicament to treat disorders of bone resorption.
- 5 2. The use according to claim 1 wherein said treatment of disorders of bone resorption is a suppression of bone resorption.
3. The use of antagonists according to claims 1 and 2 wherein said antagonists are selected from the group consisting of antibodies binding on placental growth factor, peptides binding on placental growth factor, tetrameric peptides binding on placental
- 0 growth factor or VEGFR-1, small molecules binding on placental growth factor or VEGFR-1, anti-sense nucleic acids against placental growth factor or VEGFR-1, interference RNA against placental growth factor or VEGFR-1 and ribozymes against placental growth factor or VEGFR-1.
4. The use according to claims 1, 2 and 3 wherein said bone resorption is osteoporosis.
- 5 5. A method of inhibiting a condition of enhanced bone resorption in a patient in need of such treatment, said treatment comprising administering a VEGFR-1/PIGF signalling pathway modulator in amounts effective to suppress bone resorption.
6. The method of claim 5, to treat osteoporosis in a patient in need of such treatment.
7. The method of claim 5 or 6, wherein the modulator is a PIGF inhibitor.
- 0 8. The method of claim 5 or 6, wherein the modulator is a VEGFR-1 inhibitor.